JYNT
JOINT CorpPrice & Indicators
Blended from price, positioning & fundamentals · daily-close · not investment advice.
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA from consolidated operations non-GAAP | $3.6M | Q4 2025 | — |
| Adjusted EBITDA from continuing operations non-GAAP | $1.6M | Q4 2025 | — |
| clinics opened | 29 | FY2025 | — |
| company-owned or managed clinics | 75 | FY2025 | — |
| franchise licenses sold | 31 | FY2025 | — |
| franchised clinics | 885 | FY2025 | — |
| patient visits | 14.4M | FY2025 | — |
| system-wide sales | $532.4M | FY2025 | — |
| Total clinic count | 960 | FY2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
JYNT
this stock
JOINT Corp
|
$127.87M | +2.9% | +16.2% | 39.0 | 4.7% |
|
HCA
HCA Healthcare, Inc.
|
$91.07B | -11.9% | +7.1% | 14.1 | 2.4% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$27.26B | -15.6% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$17.55B | +2.5% | -2.3% | 10.6 | 4.7% |
|
DVA
Davita Inc.
|
$15.08B | +106.8% | +6.5% | 21.9 | 7.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| JYNT | -2.6% | +8.5% | -0.1% | +2.2% | +2.9% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | -4.0% | +9.7% | -8.1% | +2.4% | -6.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.